John Horton: Biologics: Are Unsafe Drugs an ‘Acceptable Risk?’ FDA Should Say ‘No!’
John Horton: Biologics: Are Unsafe Drugs an ‘Acceptable Risk?’ FDA Should Say ‘No!’
As a matter of common sense, the FDA’s process for biosimilars shouldn’t sacrifice patient safety.
Read more on The Huffington Post
Categories: High Risk Breast Cancer Tags: 'No', acceptable, Biologics, Drugs, Horton, John, Risk, should, unsafe
FDA Grants Priority Review Designation to Denosumab Biologics License Application for the Reduction of Skeletal …
FDA Grants Priority Review Designation to Denosumab Biologics License Application for the Reduction of Skeletal …
Amgen today announced that the U.S. Food and Drug Administration has granted priority review designation to denosumab, a subcutaneous RANK Ligand inhibitor, for the treatment of bone metastases to reduce skeletal related events in patients with cancer.
Read more on PR Newswire via Yahoo! Finance
Categories: Breast Cancer Risks Tags: application, Biologics, Denosumab, Designation, Grants, License, priority, reduction, Review, Skeletal